Abstract
Background Negative symptoms are a primary driver of poor outcomes in schizophrenia spectrum disorders (SSD), but there are no FDA-approved medications or FDA-cleared therapeutics targeting negative symptoms in schizophrenia. NST-SPARK is a novel digital therapeutic targeting negative symptoms in SSD. It is a smartphone application delivering recovery-oriented cognitive therapy (CT-R), via gamified augmented reality (AR) experiences, to provide experiential learning aimed at dismantling maladaptive beliefs. In this study, we assessed a prototype (NST-SPARK v.1.5) in 20 participants with SSD and clinically significant negative symptoms. NST-SPARK v.1.5 delivers a single therapeutic module over a 1-week period. The primary objective was to determine the acceptability and feasibility of this approach. Secondary objectives were to generate descriptive findings for changes in defeatist beliefs, self-esteem, and attitudes toward goal-oriented activities.
Methods Recruitment and all study procedures were completed online. Twenty participants with schizophrenia or schizoaffective disorder were enrolled, with a range of demographic and socioeconomic status and treatment settings. Participants completed self-reports on the acceptability and feasibility of NST-SPARK v.1.5 and provided open-ended feedback through a semi-structured interview. Self-report scales on defeatist beliefs, self-esteem, and attitudes toward goal-oriented activities were completed before and after participants were introduced to NST-SPARK, and then again at a 1-week follow-up.
Results In general, participants found NST-SPARK v.1.5 to be feasible and acceptable, responding with an average response of “Agree”, indicating that the intervention was found to meet with the participants’ approval and seemed implementable. Almost all participants (19 of 20) used the app on their own prior to the 1-week follow up despite not being incentivized to do so. In addition, participants responded to open-ended feedback questions in a generally positive way. We also observed shifts in defeatist beliefs (Cohen’s d = 0.12), self-esteem (Cohen’s d = -0.21), and attitudes toward goal attainment consistent (intention: Cohen’s d = 0.13; confidence: Cohen’s d = 0.35) with intended improvements in these targeted areas. Participants were able to make substantive progress toward identified goals in 90% of cases.
Conclusions This preliminary, single-arm, unblinded study of a single-module prototype for NST-SPARK found that the approach is generally acceptable and feasible for people with SSD and negative symptoms. Engagement of the intended target of defeatist beliefs was supported by our findings but require confirmation in future randomized controlled trials. Overall, NST-SPARK is based on a promising approach and further development is warranted.
Competing Interest Statement
SXT, APB, MLB, SB, LMB, and JMK are affiliated as advisors and consultants for North Shore Therapeutics and are also employed full-time by academic institutions as described above. North Shore Therapeutics does not have any formal relationship with any of the above academic institutions. EY and WC are full-time employees of North Shore Therapeutics. In addition, SXT received research funding and serves as a consultant for Winterlight Labs, is on the advisory board and owns equity for Psyrin, and serves as a consultant for Catholic Charities Neighborhood Services and LB Pharmaceuticals. JMK has received consulting fees or honoria for lectures from Alkermes, Boerhinger Ingelheim, Cerevel, Click Therapeutics, Intracellular Therapies, H. Lundbeck, HLS, Janssen, Johnson and Johnson, Merck, Minerva, Neurocrine, Newron, Otsuka, Roche, Saladax and Teva. He is a shareholder in Cerevel, HealthRyhthms, LB Pharma, North Shore Therapeutics and The Vanguard Research Group. He has received grant support from H. Lundbeck, Otsuka, Merck, Sunovion and Valera.
Clinical Trial
NCT06653829
Funding Statement
This study was funded by North Shore Therapeutics
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The BRANY IRB gave ethical approval for this work (#23-02-339-1483).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- SSD
- schizophrenia spectrum disorder
- NST
- North Shore Therapeutics
- FDA
- United States Food and Drug Administration
- AR
- augmented reality
- VR
- virtual reality
- CT-R
- recovery-oriented cognitive therapy
- SCID-5
- Structured Clinical Interview for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
- SANS
- Scale for the Assessment of Negative Symptoms
- DBS
- Defeatist Belief Scale
- BSES
- Beck Self-Esteem Scale
- ATT
- Attitudes Toward Behavioral Change
- AIM
- Acceptability of Intervention Measure
- FIM
- Feasibility of Intervention Measure
